ArticleMolecular medicine reports2016
Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 63 citations in OpenAlex.
- Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma.Discover oncology · 2026Review
- Review
- Making Sense of Antisense lncRNAs in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Clinical significance of long non-coding RNA ZEB2-AS1 and EMT-related markers in ductal and lobular breast cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Long Non-Coding RNA ZEB2-AS1 Promotes Hepatocellular Carcinoma Progression by Regulating TheCell journal · 2022Article
- Long non-coding RNAs involved in different steps of cancer metastasis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- The correlation of long non-coding RNAs IFNG-AS1 and ZEB2-AS1 with IFN-γ and ZEB-2 expression in PBMCs and clinical features of patients with coronary artery disease.Molecular biology reports · 2022Article
- Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells.Non-coding RNA · 2022Article
- Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use.International journal of molecular sciences · 2022Review
- Long noncoding RNA network: Novel insight into hepatocellular carcinoma metastasis (Review).International journal of molecular medicine · 2021Review
- LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Potential lncRNA Biomarkers for HBV-Related Hepatocellular Carcinoma Diagnosis Revealed by Analysis on Coexpression Network.BioMed research international · 2021Article
- LncRNAs in Cancer: From garbage to Junk.Cancers · 2020Review
- Clinical significance of long non-coding RNA DUXAP8 and its protein coding genes in hepatocellular carcinoma.Journal of Cancer · 2020Article
- Fibronectin in Cancer: Friend or Foe.Cells · 2019Review
- lncRNA ZEB2-AS1 Aggravates Progression of Non-Small Cell Lung Carcinoma via Suppressing PTEN Level.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma.Journal of cellular and molecular medicine · 2019Article
- Zinc finger E‑box binding homeobox 2 functions as an oncogene in human laryngeal squamous cell carcinoma.Molecular medicine reports · 2019Article
- LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway.Molecular and cellular biochemistry · 2019Article
- Homeobox Genes and Hepatocellular Carcinoma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains one of the most common types of cancer worldwide and prognosis remains poor. Previous studies have suggested that long non‑coding RNAs (lncRNAs) may be key regulators of tumor development and progression in HCC. It has been determined that 61‑72% of transcribed regions contain lncRNAs in the antisense orientation (aslncRNAs). However, the function of aslncRNAs in HCC remains to be elucidated. The present study investigated the function of the aslncRNA zinc finger E‑box binding homeobox 2 antisense RNA 1 (ZEB2‑AS1) in 40 HCC tissues and 5 different human HCC cell lines using reverse transcription‑quantitative polymerase chain reaction. Additionally, the expression levels of ZEB2‑AS1 were downregulated by transfection of small interfering RNAs (siRNAs) to determine whether ZEB2‑AS1 is capable of affecting cell proliferation, invasion and metastasis by regulating ZEB2, vimentin, fibronectin, E‑cadherin and N‑cadherin expression levels. The results of the present study demonstrated that the expression levels of ZEB2‑AS1 were greater in HCC tissues when compared with the adjacent normal tissues. Furthermore, ZEB2‑AS1 expression was significantly associated with the size of the primary tumor, intrahepatic metastasis and tumor-node-metastasis stage. The Kaplan‑Meier survival curves suggested that patients with high ZEB2‑AS1 expression levels experienced the lowest overall and recurrence‑free survival rates compared with those that had low expression levels. In addition, the current study demonstrated that the downregulation of ZEB2‑AS1 was associated with decreased tumor growth and metastasis in HCC by the regulation of the expression levels of epithelial mesenchymal transition-induced markers. In conclusion, lncRNA ZEB2‑AS1 may be used as a valuable biomarker in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.